TAVR Still Gaining Ground Among Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has become the standard of care for patients with severe aortic stenosis and high surgical risk, and it should be considered as an option for intermediate-risk patients. In recent years, the number of low-risk patients treated with TAVR has increased. This study analyzes low-risk patients from the German Aortic Valve Registry (GARY) who underwent isolated TAVR vs. surgical treatment.

All patients with a Society of Thoracic Surgeons (STS) score <4% between 2014 and 2015 were analyzed. The result was a total of 20,549 subjects: 14,487 underwent surgery and 6062 underwent TAVR.

Patients who underwent TAVR were significantly older and had more comorbidities, so propensity score matching was used to compare in-hospital mortality at 30 days and at 1 year.

TAVR patients showed significantly higher survival rates, both in-hospital and at 30 days, than patients who underwent conventional surgery (in-hospital survival for TAVR vs. surgery: 98.5% vs. 97.3%; p = 0.003; 30-day survival for TAVR vs. surgery: 98.1% vs. 97.1%; p = 0.014).


Read also: Is Alcohol Good, Bad, or Neutral for Cardiovascular Health?


At one year, mortality was similar for both methods (90.0% vs. 91.2%; p = 0.158).

Conclusion

This first GARY Registry analysis of low-risk patients showed similar mortality for surgery and transcatheter aortic valve replacement.

ehy699-libre-para-subir

Original Title: Patients at low surgical risk as defined by the Society of Thoracic Surgeons Score undergoing isolated interventional or surgical aortic valve implantation: in-hospital data and 1-year results from the German Aortic Valve Registry (GARY).

Reference: Raffi Bekeredjian et al. European Heart Journal (2019) 40, 1323–1330.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...